Briana T. Goncalves

Ms. Goncalves’ experience includes advising: 

• Issuers and underwriters in connection with capital markets transactions, including initial public offerings and equity follow-on offerings 
• Ongoing public company clients with respect to general corporate governance matters, SEC compliance and securities law issues, disclosure and reporting obligations, including preparation of SEC disclosure documents, and continued listing requirements

Significant transactional matters include representing:

• Prometheus Biosciences, Inc. in its Series D financing, its US$219 million initial public offering, an equity follow-on offering, and the spin-off of its diagnostic services business
• Bridge Investment Group Holdings Inc. in its US$300 million initial public offering and related organizational transactions 
• Connect Biopharma Holdings Limited in its US$220 million initial public offering of American Depositary Shares 
• Avidity Biosciences, Inc. in its US$298 million initial public offering and equity follow-on offerings 
• Ligand Pharmaceuticals Incorporated in the spin-off of its antibody discovery business, OmniAb, Inc., through a Reverse Morris Trust transaction and deSPAC merger
• Searchlight Capital Partners, a global private investment firm, in its strategic investment into Sightline Payments 
• The underwriters in connection with the US$193.8 million initial public offering of Janux Therapeutics, Inc. 
• The underwriters in connection with the US$100 million initial public offering of Progenity, Inc. and several follow-on offerings of the company’s equity and debt securities